In summary, CDK1, STAT1, COL1A2, and COL1A1 identified through bioinformatics methods show promise as early diagnostic molecular markers and potential therapeutic targets for AKI in gastrointestinal cancer patients, offering valuable references for clinical treatment and personalized management. Here, COL1A2 is linked to acute kidney injury.